Fiduciary Alliance LLC Buys 6,082 Shares of United Therapeutics Corporation $UTHR

Fiduciary Alliance LLC raised its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 1,007.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,686 shares of the biotechnology company’s stock after buying an additional 6,082 shares during the period. Fiduciary Alliance LLC’s holdings in United Therapeutics were worth $3,862,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in UTHR. Torren Management LLC purchased a new position in shares of United Therapeutics during the fourth quarter worth approximately $26,000. Activest Wealth Management boosted its holdings in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares during the period. WealthCollab LLC boosted its holdings in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. grew its stake in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares in the last quarter. Finally, Entrust Financial LLC bought a new position in United Therapeutics in the fourth quarter worth approximately $31,000. 94.08% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $558.40, for a total value of $5,584,000.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at approximately $10,540,358.40. The trade was a 34.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 633,718 shares of company stock valued at $358,492,749. Company insiders own 8.60% of the company’s stock.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $549.66 on Thursday. The company has a market cap of $23.33 billion, a PE ratio of 20.29, a P/E/G ratio of 1.80 and a beta of 0.57. The firm’s 50 day moving average price is $562.63 and its 200-day moving average price is $525.08. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business’s quarterly revenue was down 1.6% on a year-over-year basis. During the same period last year, the firm earned $6.63 EPS. On average, analysts forecast that United Therapeutics Corporation will post 26.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

UTHR has been the subject of a number of research analyst reports. Royal Bank Of Canada decreased their target price on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Raymond James Financial assumed coverage on United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 price target on the stock. Cantor Fitzgerald raised their price target on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Finally, Morgan Stanley set a $516.00 price objective on United Therapeutics in a report on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.